ArticleExperimental and therapeutic medicine2010
siRNA-mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses the growth and metastasis of mouse bladder carcinoma in vivo.
Article in Experimental and therapeutic medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 12 citations in OpenAlex.
- The Antiangiogenic Effect of VEGF-A siRNA-FAM-Loaded Exosomes.Bioengineering (Basel, Switzerland) · 2025Article
- Sulfated polysaccharide ofAging · 2019Article
- Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization.Cancer gene therapy · 2017Article
- Targeted therapies in bladder cancer: an overview of in vivo research.Nature reviews. Urology · 2015Review
- AEG-1 Promotes Metastasis Through Downstream AKR1C2 and NF1 in Liver Cancer.Oncology research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growth of solid tumors is highly dependent on the formation of new blood and/or lymph vessels. Furthermore, metastases often disperse via newly formed blood or lymphatic vessels within the tumor, particularly in the case of epithelium-derived tumors. Since vascular endothelial growth factor (VEGF) signaling plays a vital role in angiogenesis and lymphangiogenesis, we used the small interfering RNA (siRNA) approach to selectively down-regulate VEGF-A, VEGF-C or VEGF receptor 3 (VEGFR-3) expression in bladder transitional carcinoma cells derived from T739 mice in an attempt to suppress tumor growth and metastasis in vivo. The synthetic siRNA was introduced into the tumor tissues by in vivo electroporation. The knockdown of VEGF-A, VEGF-C and VEGFR-3 expression significantly delayed tumor growth and reduced tumor metastasis compared to the negative controls. Thus, electroporation-mediated siRNA delivery to block the VEGF signaling pathway may provide a novel approach for the treatment or prevention of solid tumor growth and metastasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.